Innovent Biologics, Inc. (IVBXF)
OTCMKTS
· Delayed Price · Currency is USD
5.15
0.00 (0.00%)
Mar 7, 2025, 3:00 PM EST
Innovent Biologics Employees
Innovent Biologics had 4,872 employees as of December 31, 2023. The number of employees decreased by 422 or -7.97% compared to the previous year.
Employees
4,872
Change (1Y)
-422
Growth (1Y)
-7.97%
Revenue / Employee
$194,972
Profits / Employee
-$33,504
Market Cap
8.20B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 2,931 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 413 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 9 |
| Silence Therapeutics | 109 |
| Longduoduo Company | 49 |
Innovent Biologics News
- 10 days ago - Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma - PRNewsWire
- 17 days ago - NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer - PRNewsWire
- 24 days ago - Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer - PRNewsWire
- 7 weeks ago - Innovent Biologics Inc (IVBIY) Announces NMPA Approval of Limertinib for Lung Cancer Treatment - GuruFocus
- 7 weeks ago - Innovent Biologics Inc (IVBIY) Unveils Strategic Growth Plans at J.P. Morgan Healthcare Conference - GuruFocus
- 7 weeks ago - Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer - PRNewsWire
- 7 weeks ago - Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 7 weeks ago - Innovent Biologics Inc (IVBIY) Secures Breakthrough Therapy Designation for IBI343 in Advanced ... - GuruFocus